Optimization of Cancer Chemotherapy on the Basis of Pharmacokinetics and Pharmacodynamics: From Patients Enrolled in Clinical Trials to Those in the 'Real World'
スポンサーリンク
概要
- 論文の詳細を見る
Cytotoxic anticancer drugs are the most challenging therapeutic agents among all medicines with relatively narrow efficacy profiles. Therefore, medical oncologists have to practically manage the risk of severe toxic effects to optimize treatment outcomes. Dose and treatment-schedule recommendations for cytotoxic anticancer agents are determined on the basis of clinical trials. Patients enrolled in clinical trials are those likely to receive the drug in clinical practice, excluding those with conditions such as organ dysfunction, obesity, advanced age, or comorbidity. On the other hand, the 'real world' includes large numbers of such patients who do not meet the eligibility criteria of clinical trials. However, there is a paucity of data from sufficiently powered pharmacokinetic and pharmacodynamic studies to support dosage recommendations in such patients. Consequently, dose levels and treatment schedules for chemotherapy in these subjects are somewhat arbitrary and not evidence-based. Pharmacokinetic and pharmacodynamic studies of patients in the 'real world' are needed to address this issue. In this review article, we describe general aspects of clinical pharmacology in cancer patients enrolled in clinical trials and those in the 'real world,' and introduce recent findings regarding the pharmacokinetic and pharmacodynamic properties of irinotecan and S-1 in 'real world' cancer patients.
- 日本薬物動態学会の論文
日本薬物動態学会 | 論文
- COMPETITIVE DISPLACEMENT OF SERUM PROTEIN BINDING TO REGULATE PHARMACOKINETICS OF A CEREBRAL BLOOD FLOW RADIOPHARMACEUTICAL
- Studies on the Metabolic Fate of Felodipine. (IV). Identification of New Metabolites of Felodipine in Rat.
- Metabolic Fate of Pergolide Mesylate. (2): Absorption, Distribution, Excretion of 14C-Pergolide Mesylate in Rats after Repeated Administration.
- Studies on the Metabolic Fate of 3H-TJN-101. (III): Absorption, Distribution and Excretion after Multiple Oral Administration to Rats.
- Studies on the Pharmacokinetics of Perindopril Erbumine in Rats. (1): Plasma Level Profile, Distribution, Metabolism and Excretion after Single Oral Administration.